From GlobeNewswire: 2024-06-10 08:32:00

NH TherAguix’s AGuIX® radio-enhancer showcased in Scientific Reports for its quantification in brain metastases, highlighting personalized radiotherapy’s potential by combining diagnostic and therapeutic properties. Results from the NANOBRAINMETS Phase 2 clinical trial in the US demonstrate AGuIX® efficacy in treating brain metastases. Patients who received AGuIX® had concentrations ranging from 0.012 to 0.17 mg/ml in their brain metastases, showing its ability to infiltrate tumors. AGuIX® uptake was 35% higher than previous trial data, indicating a dose effect. The radio-enhancer is undergoing evaluation in four Phase II trials, expected to yield significant results by the end of 2024.

NH TherAguix, a biotech company, specializes in developing AGuIX® for precision radiotherapy in oncology, aiming to improve treatment effectiveness while minimizing damage to healthy organs. The recently published article in Scientific Reports emphasizes AGuIX®’s biomarker potential and its radio-enhancing properties when combined with radiotherapy. The collaboration between NHT and Dana Farber teams, highlighted in the study involving brain metastases patients, is paving the way for innovative therapeutic approaches. With ongoing Phase II trials and promising clinical evidence, AGuIX® could revolutionize cancer treatment and enhance patient outcomes.



Read more at GlobeNewswire: Publication of an article in Nature’s Scientific Reports